Leflunomide Combined with Alendronate Sodium for the Treatment of Osteoporosis Secondary to Rheumatoid Arthritis

February 1, 2026

View at Publisher

Ask AI

Bookmark

Share

Key Points

To investigate the efficacy of leflunomide combined with alendronate sodium in treating osteoporosis secondary to rheumatoid arthritis.
Study with 92 patients, divided into observation (leflunomide with alendronate) and control (leflunomide) groups.
Evaluated inflammatory markers, bone metabolism indicators, clinical symptoms, adverse reactions, and quality of life pre- and post-treatment.
Statistical analysis of treatment effects assessed through P-values.
Post-treatment inflammatory markers (TNF-α, IL-6, IL-17) significantly decreased in the observation group compared to control with P<0.05.
Bone density and metabolic markers significantly improved in the observation group compared to control with P<0.05.
Quality of life scores improved more in the observation group, indicating greater benefits.

Shows improved outcomes for osteoporosis in rheumatoid arthritis, indicating potential benefits of combination therapy.

No abstract yet. The journal hasn't published one we can show.

No takes yet. Share an insight, caveat, or question.

ZHAO et al. (2026) studied this question.

View at Publisher

Ask AI

Bookmark

Share